Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer

Inclusion Criteria:

Histologically confirmed Stage I or Stage II Non-Small Cell Lung Cancer
Surgically resected at least 4 weeks ago but not more than 6 months ago
Bronchoalveolar carcinomas allowed
Completion of any chemotherapy or radiation given in conjunction with Surgery (neoadjuvant or adjuvant)
No evidence of disease following initial therapy evidenced by a CXR, CT or PET scan within 6 weeks of enrollment
ECOG performance status of 0 to 2

Adequate organ and marrow function defined as follows:

Hemoglobin ≥9.0 gm/dL
Bilirubin < 2.5 x upper limit of normal
AST <2.5 x upper limit of normal
ALT <2.5 x upper limit of normal
Creatinine <3 mg/dL
Women of childbearing potential must have a negative pregnancy test and be willing to use acceptable methods of contraception through week 16.

Exclusion Criteria:

Cardiovascular disease defined as:

New York Heart Association Class III or IV (Section 19.2) congestive heart failure
hemodynamically significant valvular heart disease
myocardial infarction within the last six months
active angina pectoris
uncontrolled ventricular arrhythmias
stroke within one year
known cerebrovascular disease
History of HIV, infectious hepatitis, or chronic immunosuppressive disease
concurrent shorter courses of immunosuppressive medications during and for 16 weeks after study treatment
History of an allergic reactions to any colony stimulating factor (GCSF, GMCSF)
Female patients must not be pregnant or breastfeeding.
History of participation in any investigational drug study within 4 weeks preceding initiation of study treatment.